生产企业：Amgen
Tarlatamab (brand name IMDELLTRA) is an Amgen bispecific T-cell engager (BiTE) targeting DLL3 on tumor cells and CD3 on T cells. In the Phase 3 DeLLphi-305 study, IMDELLTRA plus durvalumab significantly improved overall survival versus durvalumab alone as first-line maintenance treatment for extensive stage small cell lung cancer (ES-SCLC), the first Phase 3 study of a BiTE therapy to demonstrate an overall survival benefit in this setting.
Tarlatamab (brand name IMDELLTRA) is an Amgen bispecific T-cell engager (BiTE) targeting DLL3 on tumor cells and CD3 on T cells. In the Phase 3 DeLLphi-305 study, IMDELLTRA plus durvalumab significantly improved overall survival versus durvalumab alone as first-line maintenance treatment for extensive stage small cell lung cancer (ES-SCLC), the first Phase 3 study of a BiTE therapy to demonstrate an overall survival benefit in this setting.
Tarlatamab (IMDELLTRA) is a first-in-class targeted immunotherapy and bispecific T-cell engager (BiTE) that binds to both DLL3 on tumor cells and CD3 on T cells, thereby activating T cells to kill DLL3-expressing small cell lung cancer (SCLC) cells. This results in the formation of a cytolytic synapse with lysis of the cancer cell. DLL3 is expressed on the surface of SCLC cells in ~85-96% of patients with SCLC but is minimally expressed on healthy cells.
共 2 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
